NCT04112147 is a Phase 2 clinical trial of Antroquinonol capsule 100mg in Chronic Hepatitis B, sponsored by Cheng-Chung Wei.

Who is sponsoring NCT04112147?

NCT04112147 is sponsored by Cheng-Chung Wei.

What drugs are being tested in NCT04112147?

Interventions in NCT04112147: Antroquinonol capsule 100mg, Antroquinonol capsule 200mg, Placebo oral capsule.

What condition does NCT04112147 study?

NCT04112147 studies Chronic Hepatitis B.

Is NCT04112147 still recruiting?

NCT04112147 is currently status unknown. Last updated 2 October 2019.

Last reviewed 2019-10-02 · How we verify

NCT04112147

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B

Status unknown Phase 2 Last updated 2 October 2019

What this trial tests

Phase 2 trial testing Antroquinonol capsule 100mg in Chronic Hepatitis B in 60 participants. Status unknown.

Timeline

10 August 2018

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Cheng-Chung Wei
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	10 August 2018
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across Taiwan

Drugs / interventions tested

Antroquinonol capsule 100mg — full drug profile →
Antroquinonol capsule 200mg — full drug profile →
Placebo oral capsule

Conditions studied

Chronic Hepatitis B — all drugs for Chronic Hepatitis B →

Sponsor

Cheng-Chung Wei — full company profile →

Who can join

Adults 20 to 75, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective: To evaluate the activity of Antroquinonol in patients with chronic hepatitis B Secondary Objective: To assess the mechanism and cytokines change of Antroquinonol in patients with chronic hepatitis B

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Hepatitis B

Currently open trials in the same condition.

NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04112147 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cheng-Chung Wei
Last refreshed: 2 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04112147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing